Incyte : FDA Approves Monjuvi Combination For R/R Follicular Lymphoma Treatment
19/6 03:33
(RTTNews) - Incyte (INCY) announced that the U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with re...